Prothena Corporation plc Ordinary Shares - PRTA STOCK NEWS

Walgreens and Prothena have announced a collaboration to enhance patient recruitment for Prothena's PRX012, a potential Alzheimer’s treatment currently in the ASCENT-2 clinical trial. Walgreens will utilize its extensive network and healthcare capabilities to identify suitable candidates, focusing on underserved communities. This trial has received Fast Track designation from the FDA, indicating its potential significance in addressing Alzheimer’s disease, which affects over 6.5 million Americans aged 65 and older. The partnership aims to create a more diverse patient population for the trial, aligning with the ENACT Act to improve inclusivity in Alzheimer’s research. Key topline data from ongoing Phase 1 studies is expected by the end of 2023.

Prothena Corporation plc (NASDAQ:PRTA) unveiled new preclinical data for its anti-amyloid beta product candidate, PRX012, at the 2023 International Conference on Alzheimer’s and Parkinson’s Diseases in Gothenburg, Sweden. The data indicates that PRX012 exhibits a 20-fold greater affinity for amyloid beta protofibrils compared to lecanemab and clears pyroglutamate-modified amyloid beta at lower concentrations than donanemab. These findings support PRX012's potential as a best-in-class treatment for Alzheimer’s disease, with implications for improved patient access and administration.

Prothena Corporation plc (NASDAQ: PRTA) will participate in a fireside chat at the Stifel 2023 Virtual CNS Days on Tuesday, March 28, 2023, at 10:30 AM ET. The event will be accessible via a live webcast through the company's investor relations section at www.prothena.com. After the live presentation, a replay of the webcast will be available for at least 90 days.

Prothena specializes in investigating therapeutics for neurodegenerative diseases and has a diverse pipeline targeting conditions like AL amyloidosis, ATTR amyloidosis, Alzheimer’s, and Parkinson’s diseases.

Prothena Corporation (NASDAQ:PRTA) showcased its leadership in Alzheimer's and Parkinson's disease treatments at the 2023 International Conference on Alzheimer's and Parkinson's Diseases held in Gothenburg, Sweden. The highlight was an oral presentation on PRX012, a next-generation anti-amyloid beta antibody, showing a 20-fold higher affinity for amyloid beta protofibrils and enhanced plaque clearance compared to existing treatments. Prothena also hosted a symposium on disease-modifying treatments and participated in panel discussions. Collaborating partner Roche presented findings on prasinezumab for Parkinson's disease.

Prothena Corporation (NASDAQ:PRTA) reported a net income of $6.3 million in Q4 2022, contrasting with a net loss of $116.9 million for the full year. Total revenue fell to $49.9 million in Q4 and $53.9 million for the year, significantly down from $1.2 million and $200.6 million in 2021, respectively. The operating cash use was $5.1 million in Q4 and $109.3 million for the year, with a cash position of $712.6 million. Noteworthy achievements include FDA clearance for PRX012’s IND application and a $40 million milestone from Novo Nordisk. The company anticipates utilizing $213 to $229 million in 2023, predicting a net cash of roughly $512 million by year end.

Prothena Corporation plc (NASDAQ:PRTA) will announce its fourth quarter and full year 2022 financial results on February 23, 2023, after U.S. market close. The company will host a live audio conference call at 4:30 PM ET to discuss the results, which will be available on its website. Prothena focuses on protein dysregulation and has a pipeline targeted at treating neurodegenerative diseases and rare peripheral amyloid diseases. Its investigational therapies aim to address conditions like AL and ATTR amyloidosis, Alzheimer's, and Parkinson's disease.

Prothena Corporation plc (NASDAQ:PRTA) announced the grant of an option to purchase 85,000 ordinary shares to a newly hired employee. This option has an exercise price of $53.67, reflecting the closing trading price on February 1, 2023. The shares will vest over four years, with 25% vesting after one year and the remainder vesting monthly over 36 months. This grant is part of the Company’s 2020 Employment Inducement Incentive Plan, approved for attracting new talent. Prothena specializes in developing therapeutics targeting neurodegenerative and rare diseases, leveraging its expertise in protein dysregulation.

Prothena Corporation (NASDAQ:PRTA) announced positive results from a Phase 1 single ascending dose (SAD) study for PRX005, an investigational antibody targeting tau pathology in Alzheimer’s disease. The study demonstrated dose-proportional concentrations of PRX005 in plasma and confirmed its safety and tolerability in healthy volunteers. Notably, PRX005 effectively penetrated the central nervous system, indicating potential effectiveness against Alzheimer’s. The ongoing Phase 1 multiple ascending dose (MAD) trial in Alzheimer’s patients is expected to report topline results by year-end 2023.

Prothena Corporation plc (NASDAQ:PRTA) announced a public offering of 3,250,000 ordinary shares at $56.50 each, aiming to raise approximately $172.4 million after expenses. The offering, closing on December 19, 2022, includes a 30-day option for underwriters to purchase an additional 487,500 shares. This offering is made under an automatic shelf registration statement filed with the SEC on March 23, 2021. Prothena focuses on developing therapeutics targeting neurodegenerative diseases.